CD19 and neoplasm: Tumor cells were positive for CD38, CD138, CD22, CD79a, MUM1, CD45, and kappa; partial positive for CD19 and EBER; negative for CD2, CD3, CD5, CD10, CD20, CD56, cyclin D1, ALKp80, HHV-8, MPO, lambda and IgG; and 5% positive for CD30; the Ki-67 positivity rate was 70% (Figures 1D–I).